# An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy.

> **NCT00750880** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 1681 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** tocilizumab [RoActemra/Actemra]

## Key facts

- **NCT ID:** NCT00750880
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 1681 (ACTUAL)
- **Last updated:** 2015-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00750880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00750880, "An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy.". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00750880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*